AstraZeneca PLC (AZN)vsPerrigo Company PLC (PRGO)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
PRGO
Perrigo Company PLC
$10.83
+1.50%
HEALTHCARE · Cap: $1.53B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1346% more annual revenue ($60.44B vs $4.18B). AZN leads profitability with a 17.2% profit margin vs -43.5%. PRGO appears more attractively valued with a PEG of 1.14. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PRGO
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+75.4%
Fair Value
$59.32
Current Price
$10.83
$48.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 3.5%
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PRGO
The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PRGO
The primary concerns for PRGO are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.52 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PRGO is a turnaround play — different risk/reward profiles.
PRGO carries more volatility with a beta of 0.54 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 45/100), backed by strong 17.2% margins and 12.5% revenue growth. PRGO offers better value entry with a 75.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Perrigo Company PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?